Hansa delivers a healthy increase in patients using IDEFIRIX.
Q3e: Two Freemelt ONE deliveries, sales SEK 9.3m, EBIT -24m Estimates down on slower-than-expected e...
Redeye updates its estimates ahead of CTEK’s Q3 report, which is due on 14 November.
Redeye updates its estimates ahead of Arise’s Q3 report which is due on 7 November.
The recent period of strong revenue growth may have come to an end in Q2, as we expect negative reve...
Ahead of Atria's Q3 report, we nudge up our estimates, owing to the warm autumn and the continued de...
Q3e: EBIT +9% y-o-y, core bitumen operations stable Rate cuts should support gradual recovery from H...
Expect continued softness on orders, comps ease from Q4 Reduce '24e-'26e EBITA by 5-3% on delayed de...
Umida Group AB (”Umida”, ”koncernen” eller ”bolaget”) meddelade den 17 oktober år 2024 utfallande av...
SRV publishes its Q3/24 figures on Thursday 24th of October.
Redeye sees only minor deviations from our expectations in Powercells’ Q3 report.
Redeye initiates coverage of Elicera Therapeutics, a Swedish clinical-stage biotech company focusing...
Profitability hampered by IAC in Scandpower Adj. EBIT margins to strengthen Negative revisions stem ...
Redeye comments on InfraCom's reported data breach, affecting over 10.
Redeye is happy to see that Railcare and LKAB have signed a 5-year agreement with a total value of ~...
Etteplan issued its second profit warning of the fiscal year prior to the Q3 report, citing ongoing ...
Weak shipping volumes and declining crude oil prices could keep organic revenue growth relatively mo...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 15 oktober att Bolaget lanserar en högprest...
Redeye takes a positive stance towards the partial divestment of Aspire.
